donepezil has been researched along with Amnesia in 34 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Amnesia: Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 74-year-old woman who presented with amnesia and positive serum anticholinergic activity (SAA), which disappeared after treatment with the cholinesterase inhibitor donepezil for 1 year." | 7.79 | Donepezil abolishes anticholinergic activity in a patient with amnesia. ( Akita, R; Hachisu, M; Hori, K; Konishi, K; Minegishi, G; Oshio, T; Tanaka, H; Tani, M; Tomioka, H; Yokoyama, S, 2013) |
| "We examined the effect of the acetylcholinesterase (AChE) inhibitor, donepezil hydrocloride (DONP), on group II metabotropic glutamate (mGlu) receptor agonist- or antagonist-induced amnesia in the step-through passive avoidance task in male mice." | 7.72 | Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. ( Irifune, M; Nishikawa, T; Ohnishi, Y; Sato, T; Tanaka, K, 2003) |
| "5 mg/kg, intraperitoneal, 30 min prior to the trial) was used to induce amnesia, and donepezil (3 mg/kg/day for 15 days) was used as a standard antiamnesic drug." | 3.81 | Evaluation of potential antiamnesic activities of aqueous extract of Vitex trifolia leaves against scopolamine induced amnesia and in normal rats. ( Chandrashekar, BR; Christopher, R; Kishore, MK; Mohanbabu, AV; Nandit, PB; Pradeepa, HD, 2015) |
| "We report the case of a 74-year-old woman who presented with amnesia and positive serum anticholinergic activity (SAA), which disappeared after treatment with the cholinesterase inhibitor donepezil for 1 year." | 3.79 | Donepezil abolishes anticholinergic activity in a patient with amnesia. ( Akita, R; Hachisu, M; Hori, K; Konishi, K; Minegishi, G; Oshio, T; Tanaka, H; Tani, M; Tomioka, H; Yokoyama, S, 2013) |
| "We examined the effect of the acetylcholinesterase (AChE) inhibitor, donepezil hydrocloride (DONP), on group II metabotropic glutamate (mGlu) receptor agonist- or antagonist-induced amnesia in the step-through passive avoidance task in male mice." | 3.72 | Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. ( Irifune, M; Nishikawa, T; Ohnishi, Y; Sato, T; Tanaka, K, 2003) |
| "The potential of heptylphysostigmine tartrate (pyrrolo [2,3b] indol-5-ol, 3,3a,8,8a-hexahydro-1,3a,8-trimethylheptylcarbamate [ester, (3aS-cis)]) (MF201), a new second-generation cholinesterase inhibitor, to antagonize scopolamine-induced amnesia in rats was assessed in an 8-arm radial maze." | 3.69 | An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. ( Braida, D; Griffini, P; Lamperti, M; Maggi, A; Paladini, E; Sala, M, 1996) |
| "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020." | 3.69 | Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. ( Kojima, J; Nakajima, K; Nakayama, K; Ochiai, M, 1997) |
| " Adverse events (AEs) were recorded throughout." | 2.75 | Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. ( Doody, RS; Ferris, S; Gao, J; Goldman, R; Murthy, AK; Salloway, S, 2010) |
| "Donepezil was well tolerated." | 2.71 | Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study. ( Benke, T; Delazer, M; Kemmler, G; Köylü, B; Trinka, E, 2005) |
| "The purpose of the study is to assess the bioavailability and neuroprotective effect of hesperetin (Hesp)-loaded nanofibers." | 1.91 | Hesperetin-loaded polymeric nanofibers: assessment of bioavailability and neuroprotective effect. ( Pattnaik, S; Yadav, YC, 2023) |
| "Donepezil (DP: 5 mg/kg) was used as a positive reference drug." | 1.56 | Cognitive Facilitation and Antioxidant Effects of an Essential Oil Mix on Scopolamine-Induced Amnesia in Rats: Molecular Modeling of In Vitro and In Vivo Approaches. ( Boiangiu, RS; Brinza, I; Cioanca, O; Erdogan Orhan, I; Eren, G; Ertas, H; Gündüz, E; Hancianu, M; Hritcu, L, 2020) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "To evaluate the cost effectiveness of genetic screening for the apolipoprotein (APOE) ε4 allele in combination with preventive donepezil treatment in comparison with the standard of care for amnestic mild cognitive impairment (AMCI) patients in Canada." | 1.38 | Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. ( Beca, J; Black, S; Djalalov, S; Hoch, JS; Moretti, M; Musa, Z; Saposnik, G; Siminovitch, K; Yong, J, 2012) |
| "A total of 18 patients with Alzheimer's disease and 12 patients with amnesic syndrome received study-test sessions under four different study conditions: errorless/errorful and effortless/effortful." | 1.36 | Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome. ( Komatsu, S; Mimura, M, 2010) |
| "Donepezil is a potent acetylcholinesterase inhibitor that also interacts with the sigma1 receptor, an intracellular neuromodulatory protein." | 1.33 | Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. ( Ieni, J; Maurice, T; Meunier, J, 2006) |
| " The reversal of scopolamine-induced impairment was characterized by an inverted U-shaped dose-response curve." | 1.30 | Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF268). ( Braida, D; Colibretti, L; Griffini, P; Lamperti, M; Paladini, E; Sala, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha, SK | 1 |
| Shrivastava, SK | 2 |
| Więckowska, A | 1 |
| Więckowski, K | 1 |
| Bajda, M | 1 |
| Brus, B | 1 |
| Sałat, K | 1 |
| Czerwińska, P | 1 |
| Gobec, S | 1 |
| Filipek, B | 1 |
| Malawska, B | 1 |
| Singla, S | 1 |
| Piplani, P | 1 |
| Gutti, G | 1 |
| Kakarla, R | 1 |
| Kumar, D | 1 |
| Beohar, M | 1 |
| Ganeshpurkar, A | 1 |
| Kumar, A | 1 |
| Krishnamurthy, S | 1 |
| Singh, SK | 1 |
| Choubey, PK | 1 |
| Tripathi, A | 1 |
| Sharma, P | 1 |
| de Mello, JE | 1 |
| Luduvico, KP | 1 |
| Dos Santos, A | 1 |
| Teixeira, FC | 1 |
| de Souza Cardoso, J | 1 |
| de Aguiar, MSS | 1 |
| Cunico, W | 1 |
| Vizzotto, M | 1 |
| Stefanello, F | 1 |
| Spanevello, R | 1 |
| Yadav, YC | 1 |
| Pattnaik, S | 1 |
| Boiangiu, RS | 1 |
| Brinza, I | 1 |
| Hancianu, M | 1 |
| Erdogan Orhan, I | 1 |
| Eren, G | 1 |
| Gündüz, E | 1 |
| Ertas, H | 1 |
| Hritcu, L | 1 |
| Cioanca, O | 1 |
| Zhao, J | 1 |
| Li, K | 1 |
| Wang, Y | 1 |
| Li, D | 1 |
| Wang, Q | 1 |
| Xie, S | 1 |
| Wang, J | 2 |
| Zuo, Z | 1 |
| Kaur, R | 1 |
| Singh, V | 1 |
| Shri, R | 1 |
| Zhang, J | 1 |
| Zhou, GS | 1 |
| Tan, YJ | 1 |
| Tao, HJ | 1 |
| Chen, JQ | 1 |
| Pu, ZJ | 1 |
| Ma, JY | 1 |
| She, W | 1 |
| Kang, A | 1 |
| Zhu, Y | 1 |
| Liu, P | 1 |
| Zhu, ZH | 1 |
| Shi, XQ | 1 |
| Tang, YP | 1 |
| Duan, JA | 1 |
| Mohanbabu, AV | 1 |
| Kishore, MK | 1 |
| Chandrashekar, BR | 1 |
| Pradeepa, HD | 1 |
| Christopher, R | 1 |
| Nandit, PB | 1 |
| Ghumatkar, PJ | 1 |
| Patil, SP | 1 |
| Jain, PD | 1 |
| Tambe, RM | 1 |
| Sathaye, S | 1 |
| Cavedo, E | 1 |
| Dubois, B | 1 |
| Colliot, O | 1 |
| Lista, S | 1 |
| Croisile, B | 1 |
| Tisserand, GL | 1 |
| Touchon, J | 1 |
| Bonafe, A | 1 |
| Ousset, PJ | 1 |
| Rouaud, O | 1 |
| Ricolfi, F | 1 |
| Vighetto, A | 1 |
| Pasquier, F | 1 |
| Galluzzi, S | 1 |
| Delmaire, C | 1 |
| Ceccaldi, M | 1 |
| Girard, N | 1 |
| Lehericy, S | 1 |
| Duveau, F | 1 |
| Chupin, M | 1 |
| Sarazin, M | 1 |
| Dormont, D | 1 |
| Hampel, H | 1 |
| Malik, J | 1 |
| Kaur, J | 1 |
| Choudhary, S | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| van Straaten, EC | 1 |
| Harvey, D | 1 |
| Scheltens, P | 1 |
| Barkhof, F | 1 |
| Petersen, RC | 2 |
| Thal, LJ | 2 |
| Jack, CR | 1 |
| DeCarli, C | 1 |
| Doody, RS | 1 |
| Ferris, S | 1 |
| Salloway, S | 1 |
| Goldman, R | 1 |
| Gao, J | 1 |
| Murthy, AK | 1 |
| Mimura, M | 1 |
| Komatsu, S | 1 |
| Djalalov, S | 1 |
| Yong, J | 1 |
| Beca, J | 1 |
| Black, S | 1 |
| Saposnik, G | 1 |
| Musa, Z | 1 |
| Siminovitch, K | 1 |
| Moretti, M | 1 |
| Hoch, JS | 1 |
| Konishi, K | 1 |
| Hori, K | 1 |
| Tomioka, H | 1 |
| Minegishi, G | 1 |
| Tani, M | 1 |
| Tanaka, H | 1 |
| Akita, R | 1 |
| Yokoyama, S | 1 |
| Oshio, T | 1 |
| Hachisu, M | 1 |
| Kosaka, K | 1 |
| Sato, T | 1 |
| Tanaka, K | 1 |
| Ohnishi, Y | 1 |
| Irifune, M | 1 |
| Nishikawa, T | 1 |
| Wang, LN | 1 |
| Wang, W | 1 |
| Zhang, XH | 1 |
| Ma, L | 1 |
| Yin, H | 1 |
| Li, DJ | 1 |
| Benke, T | 1 |
| Köylü, B | 1 |
| Delazer, M | 1 |
| Trinka, E | 1 |
| Kemmler, G | 1 |
| Meunier, J | 2 |
| Ieni, J | 2 |
| Maurice, T | 2 |
| Fleisher, AS | 1 |
| Sowell, BB | 1 |
| Taylor, C | 1 |
| Gamst, AC | 1 |
| Agrawal, R | 1 |
| Tyagi, E | 1 |
| Shukla, R | 1 |
| Nath, C | 1 |
| Braida, D | 2 |
| Paladini, E | 2 |
| Griffini, P | 2 |
| Lamperti, M | 2 |
| Maggi, A | 1 |
| Sala, M | 2 |
| Cheng, DH | 1 |
| Ren, H | 1 |
| Tang, XC | 2 |
| Kojima, J | 1 |
| Nakajima, K | 1 |
| Ochiai, M | 1 |
| Nakayama, K | 1 |
| Colibretti, L | 1 |
| Wang, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders[NCT00403520] | Phase 4 | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for donepezil and Amnesia
| Article | Year |
|---|---|
[Amnestic syndrome].
Topics: Amnesia; Cholinesterase Inhibitors; Diagnostic and Statistical Manual of Mental Disorders; Donepezil | 2003 |
5 trials available for donepezil and Amnesia
| Article | Year |
|---|---|
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cerebral Cortex; Cognitive Dysfunction; Disease | 2016 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
Topics: Adult; Aged; Aged, 80 and over; Amnesia; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study.
Topics: Adult; Amnesia; Aneurysm, Ruptured; Case-Control Studies; Cholinesterase Inhibitors; Dementia; Donep | 2005 |
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Apolipoprotein | 2007 |
28 other studies available for donepezil and Amnesia
| Article | Year |
|---|---|
Synthesis, evaluation and molecular dynamics study of some new 4-aminopyridine semicarbazones as an antiamnesic and cognition enhancing agents.
Topics: Acetylcholinesterase; Aminopyridines; Amnesia; Animals; Behavior, Animal; Binding Sites; Brain; Buty | 2013 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
Coumarin derivatives as potential inhibitors of acetylcholinesterase: Synthesis, molecular docking and biological studies.
Topics: Acetylcholinesterase; Amnesia; Animals; Cholinesterase Inhibitors; Coumarins; Humans; Mice; Molecula | 2016 |
Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcho | 2019 |
Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcholinester | 2020 |
Therapeutic potential of blackberry extract in the preventing memory deficits and neurochemical alterations in the cerebral cortex, hippocampus and cerebellum of a rat model with amnesia.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Cerebellum; Cerebral Cortex; Donepezil; Hippoc | 2023 |
Hesperetin-loaded polymeric nanofibers: assessment of bioavailability and neuroprotective effect.
Topics: Acetylcholinesterase; Amnesia; Animals; Biological Availability; Donepezil; Maze Learning; Nanofiber | 2023 |
Cognitive Facilitation and Antioxidant Effects of an Essential Oil Mix on Scopolamine-Induced Amnesia in Rats: Molecular Modeling of In Vitro and In Vivo Approaches.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Behavior Rating Scale; Brain; Butyrylcholinest | 2020 |
Enhanced anti-amnestic effect of donepezil by Ginkgo biloba extract (EGb 761) via further improvement in pro-cholinergic and antioxidative activities.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Behavior, Animal; Brain; Cell Line; Cholinergi | 2021 |
Anti-amnesic effects of Ganoderma species: A possible cholinergic and antioxidant mechanism.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Biphenyl | 2017 |
Studies of the Anti-amnesic Effects and Mechanisms of Single and Combined Use of Donepezil and Ginkgo Ketoester Tablet on Scopolamine-Induced Memory Impairment in Mice.
Topics: Acetylcholine; Acetylcholinesterase; Amnesia; Animals; Benzothiazoles; Biphenyl Compounds; Brain-Der | 2019 |
Evaluation of potential antiamnesic activities of aqueous extract of Vitex trifolia leaves against scopolamine induced amnesia and in normal rats.
Topics: Administration, Oral; Amnesia; Animals; Cognition; Donepezil; Dose-Response Relationship, Drug; Inda | 2015 |
Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Animals; Antioxidants; Brain-Derived Neurotrophic | 2015 |
Standardized extract of Lactuca sativa Linn. and its fractions abrogates scopolamine-induced amnesia in mice: A possible cholinergic and antioxidant mechanism.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Behavior, Animal; Catalase; Cholinergic Agents | 2018 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cues; Donepezil; Fem | 2010 |
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.
Topics: Aged; Aged, 80 and over; Amnesia; Canada; Case-Control Studies; Chemoprevention; Cognitive Dysfuncti | 2012 |
Donepezil abolishes anticholinergic activity in a patient with amnesia.
Topics: Aged; Amnesia; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Female; Humans; Indans; | 2013 |
Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice.
Topics: Amino Acids; Amnesia; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cyclopropanes; Donepez | 2003 |
[An interventional study on amnestic mild cognitive impairment with small dose donepezil].
Topics: Aged; Aged, 80 and over; Amnesia; Aspartic Acid; Cognition; Cognition Disorders; Creatine; Donepezil | 2004 |
Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas.
Topics: Amnesia; Animals; Avoidance Learning; Behavior, Animal; Carbon Monoxide; Cholinesterase Inhibitors; | 2006 |
The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.
Topics: Amnesia; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Donepezil; Dose-Respo | 2006 |
Effect of insulin and melatonin on acetylcholinesterase activity in the brain of amnesic mice.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Avoidance Learning; Brain; Cholinergic Fibers; | 2008 |
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Topics: Amnesia; Analysis of Variance; Animals; Behavior, Animal; Cholinesterase Inhibitors; Donepezil; Dose | 1996 |
Huperzine A, a novel promising acetylcholinesterase inhibitor.
Topics: Acetylcholinesterase; Alkaloids; Amnesia; Animals; Butyrylcholinesterase; Cerebral Cortex; Cholinerg | 1996 |
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amnesia; Animals; Butyrylcholinesterase; C | 1997 |
Long-lasting antiamnesic effect of a novel anticholinesterase inhibitor (MF268).
Topics: Amnesia; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Indans; Male; Maze Learnin | 1998 |
Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine.
Topics: Alkaloids; Amnesia; Animals; Cholinesterase Inhibitors; Donepezil; Indans; Male; Maze Learning; Musc | 1998 |